Literature DB >> 15033558

The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation.

Leida M Lamers1, René C J A van Vliet.   

Abstract

In 2002, the Dutch government implemented a Pharmacy-based Cost Group (PCG) model in the social health insurance sector. This model uses specific types of medication prescribed to individuals in a base year as markers for chronic conditions, which are then employed to adjust capitation payments to their sickness fund in the subsequent year. In this study, a classification of prescribed medication is derived for 22 chronic conditions, based on an assessment of the relation between prescribed medication and diagnoses indicated by physicians on their prescriptions. Of the 22 chronic conditions in this classification, 13 were included in the PCG model that is currently used in the Netherlands.

Mesh：

Year:  2004        PMID： 15033558     DOI： 10.1016/j.healthpol.2003.09.001

Source DB:  PubMed          Journal:  Health Policy        ISSN： 0168-8510            Impact factor:   2.980


  34 in total

1.  Overpaying morbidity adjusters in risk equalization models.

Authors:  R C van Kleef; R C J A van Vliet; W P M M van de Ven
Journal:  Eur J Health Econ       Date:  2015-09-29

2.  Improving the prediction model used in risk equalization: cost and diagnostic information from multiple prior years.

Authors:  S H C M van Veen; R C van Kleef; W P M M van de Ven; R C J A van Vliet
Journal:  Eur J Health Econ       Date:  2014-02-12

3.  Change in colorectal cancer (CRC) testing rates associated with the introduction of the first organized screening program in canton Uri, Switzerland: Evidence from insurance claims data analyses from 2010 to 2018.

Authors:  Sarah Bissig; Lamprini Syrogiannouli; Rémi Schneider; Kali Tal; Kevin Selby; Cinzia Del Giovane; Jean-Luc Bulliard; Oliver Senn; Cyril Ducros; Christian P R Schmid; Urs Marbet; Reto Auer
Journal:  Prev Med Rep       Date:  2022-06-10

4.  Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.

Authors:  Naomi C Sacks; James F Burgess; Howard J Cabral; Steven D Pizer; Marie E McDonnell
Journal:  J Gen Intern Med       Date:  2013-02-13       Impact factor: 5.128

5.  The impact of an individualized risk-adjusted approach on hypertension treatment in primary care.

Authors:  Stefan Zechmann; Oliver Senn; Fabio Valeri; Stefan Neuner-Jehle; Thomas Rosemann; Sima Djalali
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-01-06       Impact factor: 3.738

6.  Outpatient costs in pharmaceutically treated diabetes patients with and without a diagnosis of depression in a Dutch primary care setting.

Authors:  Judith E Bosmans; Marcel C Adriaanse
Journal:  BMC Health Serv Res       Date:  2012-02-23       Impact factor: 2.655

7.  General Practitioners' vitamin K antagonist monitoring is associated with better blood pressure control in patients with hypertension--a cross-sectional database study.

Authors:  Sven Streit; Vladimir Kaplan; André Busato; Sima Djalali; Oliver Senn; Damian N Meli
Journal:  BMC Cardiovasc Disord       Date:  2015-06-10       Impact factor: 2.298

8.  Official statistics and claims data records indicate non-response and recall bias within survey-based estimates of health care utilization in the older population.

Authors:  Matthias Hunger; Larissa Schwarzkopf; Margit Heier; Annette Peters; Rolf Holle
Journal:  BMC Health Serv Res       Date:  2013-01-03       Impact factor: 2.655

9.  Place of death and health care utilization for people in the last 6 months of life in Switzerland: a retrospective analysis using administrative data.

Authors:  Oliver Reich; Andri Signorell; André Busato
Journal:  BMC Health Serv Res       Date:  2013-03-25       Impact factor: 2.655

10.  Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population.

Authors:  Barbara Hasse; Philip E Tarr; Pedro Marques-Vidal; Gerard Waeber; Martin Preisig; Vincent Mooser; Fabio Valeri; Sima Djalali; Rauch Andri; Enos Bernasconi; Alexandra Calmy; Matthias Cavassini; Pietro Vernazza; Manuel Battegay; Rainer Weber; Oliver Senn; Peter Vollenweider; Bruno Ledergerber; V Aubert; J Barth; M Battegay; E Bernasconi; J Böni; H C Bucher; C Burton-Jeangros; A Calmy; M Cavassini; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; C A Fux; M Gorgievski; H Günthard; D Haerry; B Hasse; H H Hirsch; I Hösli; C Kahlert; L Kaiser; O Keiser; T Klimkait; R Kouyos; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; K Metzner; N Müller; D Nadal; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; F Schöni-Affolter; P Schmid; D Schultze; J Schüpbach; R Speck; C Staehelin; P Tarr; A Telenti; A Trkola; P Vernazza; R Weber; S Yerly; Aubry Jean-Michel; Bochud Murielle; Gaspoz Jean Michel; Hock Christoph; Lüscher Thomas; Marques Vidal Pedro; Mooser Vincent; Paccaud Fred; Preisig Martin; Vollenweider Peter; Von Känel Roland; Vladeta Aidacic; Waeber Gerard; Beriger Jürg; Bertschi Markus; Bhend Heinz; Büchi Martin; Bürke Hans-Ulrich; Bugmann Ivo; Cadisch Reto; Charles Isabelle; Chmiel Corinne; Djalali Sima; Duner Peter; Erni Simone; Forster Andrea; Frei Markus; Frey Claudius; Frey Jakob; Gibreil Musa Ali; Günthard Matthias; Haller Denis; Hanselmann Marcel; Häuptli Walter; Heininger Simon; Huber Felix; Hufschmid Paul; Kaiser Eva; Kaplan Vladimir; Klaus Daniel; Koch Stephan; Köstner Beat; Kuster Benedict; Kuster Heidi; Ladan Vesna; Lauffer Giovanni; Leibundgut Hans Werner; Luchsinger Phillippe; Lüscher Severin; Maier Christoph; Martin Jürgen; Meli Damian; Messerli Werner; Morger Titus; Navarro Valentina; Rizzi Jakob; Rosemann Thomas; Sajdl Hana; Schindelek Frank; Schlatter Georg; Senn Oliver; Somaini Pietro; Staeger Jacques; Staehelin Alfred; Steinegger Alois; Steurer Claudia; Suter Othmar; Truong The Phuoc; Vecellio Marco; Violi Alessandro; Von Allmen René; Waeckerlin Hans; Weber Fritz; Weber-Schär Johanna; Widler Joseph; Zoller Marco
Journal:  Open Forum Infect Dis       Date:  2015-07-08       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.